{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:06:42Z","timestamp":1788862002174,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>Postoperative radio-hormone therapy plays a significant role in management of prostate cancer after radical prostatectomy (RP), particularly in efforts to reduce biochemical recurrence (BCR), distant metastasis, and improve overall survival. BCR rates can be upwards of 50\u201370% at 5\u00a0years, highlighting the need for optimized risk stratification and consideration of multimodal treatment approaches. The purpose of this review is to highlight evidence-based treatment recommendations, and call attention to the importance of personalized therapeutic strategies after RP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>Both radiotherapy (RT) and ADT have been shown to optimize survival outcomes and to reduce disease progression in patients with persistent PSA, pathologic lymph-node positive disease, and adverse pathology. Early salvage RT (SRT) is typically a preferred treatment approach as it allows for treatment intensification only when clinically indicated, avoiding unnecessary radiation in men who may never recur. ADT is often added to external beam radiation therapy (EBRT) to enhance treatment efficacy, particularly in patients with high-risk features, though in selected lower-risk scenarios, radiation alone may be sufficient. Short-term ADT is appropriate for low-intermediate risk patients and long-term is appropriate for patients with advanced pathological features or nodal involvement. For certain high-risk pathologic findings, such as positive surgical margins and seminal vesicle invasion (T3b), adjuvant RT (aRT) may be indicated to optimize disease control.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Overall, radio-hormone therapy plays a significant role in the postoperative setting by reducing the risk of recurrence and disease progression, and improving survival outcomes. There are several well-validated tools that may offer personalized risk assessments to identify which patients may most benefit from adjuvant or salvage therapies. Finally, the optimal use of such therapies continues to be investigated with ongoing trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11912-025-01694-y","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T20:24:09Z","timestamp":1749759849000},"page":"975-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Defining the Role of Postoperative Radio-Hormone Therapy in Prostate Cancer"],"prefix":"10.1007","volume":"27","author":[{"given":"Harshitha","family":"Dudipala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Dabbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshitij","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika D.","family":"Gurnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"2","key":"1694_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/s0090-4295(02)02268-9","volume":"61","author":"SJ Freedland","year":"2003","unstructured":"Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen Urology. 2003;61(2):365\u20139. https:\/\/doi.org\/10.1016\/s0090-4295(02)02268-9.","journal-title":"Prostate-specific antigen Urology"},{"issue":"24","key":"1694_CR2","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","volume":"24","author":"AJ Stephenson","year":"2006","unstructured":"Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24(24):3973\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.04.0756.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1694_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/JU.0000000000003892","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024;211(4):509\u201317. https:\/\/doi.org\/10.1097\/JU.0000000000003892.","journal-title":"J Urol."},{"issue":"6","key":"1694_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.eururo.2014.09.019","volume":"67","author":"JA Brockman","year":"2015","unstructured":"Brockman JA, Alanee S, Vickers AJ, et al. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. Eur Urol. 2015;67(6):1160\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2014.09.019.","journal-title":"Eur Urol"},{"issue":"2","key":"1694_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s13193-012-0142-6","volume":"3","author":"M Adhyam","year":"2012","unstructured":"Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol. 2012;3(2):120\u20139. https:\/\/doi.org\/10.1007\/s13193-012-0142-6.","journal-title":"Indian J Surg Oncol"},{"issue":"2","key":"1694_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/01.ju.0000045749.90353.c7","volume":"169","author":"M Han","year":"2003","unstructured":"Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517\u201323. https:\/\/doi.org\/10.1097\/01.ju.0000045749.90353.c7.","journal-title":"J Urol"},{"key":"1694_CR7","doi-asserted-by":"publisher","unstructured":"Tzeng M, Vertosick E, Basourakos SP, et al. Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms.\u00a0Eur Urol Open Sci. 2021;30:13\u201315. Published 2021 Jun 15. https:\/\/doi.org\/10.1016\/j.euros.2021.06.002","DOI":"10.1016\/j.euros.2021.06.002"},{"issue":"5","key":"1694_CR8","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.1999.17.5.1499","volume":"17","author":"MW Kattan","year":"1999","unstructured":"Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17(5):1499\u2013507. https:\/\/doi.org\/10.1200\/JCO.1999.17.5.1499.","journal-title":"J Clin Oncol"},{"issue":"28","key":"1694_CR9","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1200\/JCO.2005.01.867","volume":"23","author":"AJ Stephenson","year":"2005","unstructured":"Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23(28):7005\u201312. https:\/\/doi.org\/10.1200\/JCO.2005.01.867.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1694_CR10","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1002\/cncr.26169","volume":"117","author":"MR Cooperberg","year":"2011","unstructured":"Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039\u201346. https:\/\/doi.org\/10.1002\/cncr.26169.","journal-title":"Cancer"},{"issue":"6","key":"1694_CR11","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.juro.2014.12.020","volume":"193","author":"D Tilki","year":"2015","unstructured":"Tilki D, Mandel P, Schlomm T, et al. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. J Urol. 2015;193(6):1970\u20135. https:\/\/doi.org\/10.1016\/j.juro.2014.12.020.","journal-title":"J Urol"},{"issue":"3","key":"1694_CR12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.juro.2010.10.057","volume":"185","author":"SE Eggener","year":"2011","unstructured":"Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185(3):869\u201375. https:\/\/doi.org\/10.1016\/j.juro.2010.10.057.","journal-title":"J Urol"},{"issue":"17","key":"1694_CR13","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591\u20137. https:\/\/doi.org\/10.1001\/jama.281.17.1591.","journal-title":"JAMA"},{"issue":"3","key":"1694_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","volume":"79","author":"NK Jairath","year":"2021","unstructured":"Jairath NK, Dal Pra A, Vince R Jr, et al. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol. 2021;79(3):374\u201383. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.021.","journal-title":"Eur Urol"},{"issue":"9","key":"1694_CR15","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.annonc.2022.05.007","volume":"33","author":"A Dal Pra","year":"2022","unstructured":"Dal Pra A, Ghadjar P, Hayoz S, et al. Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09\/10 randomized clinical trial. Ann Oncol. 2022;33(9):950\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.007.","journal-title":"Ann Oncol"},{"key":"1694_CR16","unstructured":"Adra N. Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel (NRG-GU002). Indiana University Melvin and Bren Simon Comprehensive Cancer Center. https:\/\/cancer.iu.edu\/patients\/clinical-trials\/33535"},{"key":"1694_CR17","unstructured":"Desai N, Berlin A. NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE). NRG Oncology. https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/nrg-gu010-1"},{"key":"1694_CR18","doi-asserted-by":"publisher","unstructured":"Feng FY, Huang HC, Spratt DE, et al. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG\/RTOG 9601 Randomized Clinical Trial [published correction appears in JAMA Oncol. 2021;7(4):639. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0552.].\u00a0JAMA Oncol. 2021;7(4):544\u2013552. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7671","DOI":"10.1001\/jamaoncol.2021.0552"},{"issue":"3","key":"1694_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245\u201355. https:\/\/doi.org\/10.1016\/S1470-2045(10)70295-3.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1694_CR20","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2012.46.4396","volume":"31","author":"MR Cooperberg","year":"2013","unstructured":"Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31(11):1428\u201334. https:\/\/doi.org\/10.1200\/JCO.2012.46.4396.","journal-title":"J Clin Oncol"},{"key":"1694_CR21","doi-asserted-by":"publisher","unstructured":"Zhao Z, Weickmann S, Jung M, et al. A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature.\u00a0Cancers (Basel). 2019;11(10):1603. Published 2019 Oct 21. https:\/\/doi.org\/10.3390\/cancers11101603","DOI":"10.3390\/cancers11101603"},{"issue":"11","key":"1694_CR22","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021;7(11):1635\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1694_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/JU.0000000000004032","volume":"212","author":"CD Bahler","year":"2024","unstructured":"Bahler CD, Tachibana I, Tann M, et al. Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial. J Urol. 2024;212(2):290\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000004032.","journal-title":"J Urol"},{"key":"1694_CR24","doi-asserted-by":"publisher","unstructured":"Armstrong WR, Kishan AU, Booker KM, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774) [published correction appears in Eur Urol. 2025 Jan;87(1):97-99. https:\/\/doi.org\/10.1016\/j.eururo.2024.10.022.].\u00a0Eur Urol. 2024;86(1):52-60. https:\/\/doi.org\/10.1016\/j.eururo.2024.01.012","DOI":"10.1016\/j.eururo.2024.10.022"},{"issue":"1","key":"1694_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1590\/S1677-5538.IBJU.2016.0656","volume":"44","author":"R Tourinho-Barbosa","year":"2018","unstructured":"Tourinho-Barbosa R, Srougi V, Nunes-Silva I, et al. Biochemical recurrence after radical prostatectomy: what does it mean? Int Braz J Urol. 2018;44(1):14\u201321. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2016.0656.","journal-title":"Int Braz J Urol"},{"issue":"4","key":"1694_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41391-023-00728-5","volume":"27","author":"F Preisser","year":"2024","unstructured":"Preisser F, Incesu RB, Rajwa P, et al. Impact of persistent PSA after salvage radical prostatectomy: a multicenter study. Prostate Cancer Prostatic Dis. 2024;27(4):686\u201392. https:\/\/doi.org\/10.1038\/s41391-023-00728-5.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1694_CR27","doi-asserted-by":"publisher","unstructured":"Siech C, Wenzel M, Lange C, et al. The Association between Patient Characteristics and Biochemical Recurrence after Radical Prostatectomy.\u00a0Medicina (Kaunas). 2024;60(7):1119. Published 2024 Jul 11. https:\/\/doi.org\/10.3390\/medicina60071119","DOI":"10.3390\/medicina60071119"},{"issue":"6","key":"1694_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.eururo.2013.05.025","volume":"64","author":"S Punnen","year":"2013","unstructured":"Punnen S, Cooperberg MR, D\u2019Amico AV, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2013;64(6):905\u201315. https:\/\/doi.org\/10.1016\/j.eururo.2013.05.025.","journal-title":"Eur Urol"},{"key":"1694_CR29","doi-asserted-by":"publisher","unstructured":"Do Carmo Silva J, Vesely S, Luksanova H, Prusa R, Babjuk M. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.\u00a0Tumour Biol. 2021;43(1):197\u2013207. https:\/\/doi.org\/10.3233\/TUB-211509","DOI":"10.3233\/TUB-211509"},{"issue":"6","key":"1694_CR30","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1245\/s10434-024-14999-2","volume":"31","author":"M Shiota","year":"2024","unstructured":"Shiota M, Takamatsu D, Matsui Y, et al. Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy. Ann Surg Oncol. 2024;31(6):3872\u20139. https:\/\/doi.org\/10.1245\/s10434-024-14999-2.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1694_CR31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.4143\/crt.2023.1264","volume":"56","author":"J Suh","year":"2024","unstructured":"Suh J, Jeong IG, Jeon HG, et al. Bilateral Seminal Vesicle Invasion as a Strong Prognostic Indicator in T3b Prostate Cancer Patients Following Radical Prostatectomy: A Comprehensive, Multicenter. Long-term Follow-up Study Cancer Res Treat. 2024;56(3):885\u201392. https:\/\/doi.org\/10.4143\/crt.2023.1264.","journal-title":"Long-term Follow-up Study Cancer Res Treat"},{"issue":"11","key":"1694_CR32","doi-asserted-by":"publisher","first-page":"6936","DOI":"10.1245\/s10434-023-13780-1","volume":"30","author":"T Komori","year":"2023","unstructured":"Komori T, Matsumoto K, Kosaka T, et al. Long-Term Prognosis and Treatment Strategy of Persistent PSA After Radical Prostatectomy. Ann Surg Oncol. 2023;30(11):6936\u201342. https:\/\/doi.org\/10.1245\/s10434-023-13780-1.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1694_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12094-021-02700-y","volume":"24","author":"D Milonas","year":"2022","unstructured":"Milonas D, Laenen A, Venclovas Z, Jarusevicius L, Devos G, Joniau S. Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy. Clin Transl Oncol. 2022;24(2):371\u20138. https:\/\/doi.org\/10.1007\/s12094-021-02700-y.","journal-title":"Clin Transl Oncol"},{"key":"1694_CR34","doi-asserted-by":"publisher","unstructured":"Ballas LK, Reddy CA, Han HR, et al. Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study.\u00a0Pract Radiat Oncol. Published online December 27, 2024. https:\/\/doi.org\/10.1016\/j.prro.2024.12.006","DOI":"10.1016\/j.prro.2024.12.006"},{"issue":"6","key":"1694_CR35","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","volume":"7","author":"EM Messing","year":"2006","unstructured":"Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(06)70700-8.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1694_CR36","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/pros.24085","volume":"81","author":"SL Washington 3rd","year":"2021","unstructured":"Washington SL 3rd, Cowan JE, Herlemann A, et al. Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer. Prostate. 2021;81(2):102\u20138. https:\/\/doi.org\/10.1002\/pros.24085.","journal-title":"Prostate"},{"issue":"10338","key":"1694_CR37","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399(10338):1886\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(21)01790-6.","journal-title":"Lancet"},{"key":"1694_CR38","doi-asserted-by":"publisher","unstructured":"Kapoor R, Deek MP, McIntyre R, et al. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).\u00a0BMC Cancer. 2019;19(1):572. Published 2019 Jun 13. https:\/\/doi.org\/10.1186\/s12885-019-5805-z","DOI":"10.1186\/s12885-019-5805-z"},{"issue":"5","key":"1694_CR39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017;376(5):417\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1607529.","journal-title":"N Engl J Med"},{"issue":"1","key":"1694_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.radonc.2015.10.028","volume":"118","author":"D Bartkowiak","year":"2016","unstructured":"Bartkowiak D, Bottke D, Thamm R, Siegmann A, Hinkelbein W, Wiegel T. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival. Radiother Oncol. 2016;118(1):131\u20135. https:\/\/doi.org\/10.1016\/j.radonc.2015.10.028.","journal-title":"Radiother Oncol"},{"issue":"6","key":"1694_CR41","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.eururo.2016.07.028","volume":"71","author":"N Fossati","year":"2017","unstructured":"Fossati N, Karnes RJ, Boorjian SA, et al. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. Eur Urol. 2017;71(6):886\u201393. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.028.","journal-title":"Eur Urol"},{"issue":"3","key":"1694_CR42","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","volume":"181","author":"IM Thompson","year":"2009","unstructured":"Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956\u201362. https:\/\/doi.org\/10.1016\/j.juro.2008.11.032.","journal-title":"J Urol"},{"issue":"9485","key":"1694_CR43","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(05)67101-2","volume":"366","author":"M Bolla","year":"2005","unstructured":"Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(05)67101-2.","journal-title":"Lancet"},{"issue":"18","key":"1694_CR44","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1200\/JCO.2008.18.9563","volume":"27","author":"T Wiegel","year":"2009","unstructured":"Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96\u201302\/AUO AP 09\/95. J Clin Oncol. 2009;27(18):2924\u201330. https:\/\/doi.org\/10.1200\/JCO.2008.18.9563.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1694_CR45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12094-017-1709-z","volume":"20","author":"A Herv\u00e1s","year":"2018","unstructured":"Herv\u00e1s A, G\u00f3mez-Caama\u00f1o A, Casa\u00f1a M, et al. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database. Clin Transl Oncol. 2018;20(2):193\u2013200. https:\/\/doi.org\/10.1007\/s12094-017-1709-z.","journal-title":"Clin Transl Oncol"},{"key":"1694_CR46","doi-asserted-by":"publisher","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.\u00a0Lancet Oncol. 2020;21(10):1331\u20131340. https:\/\/doi.org\/10.1016\/S1470-2045(20)30456-3","DOI":"10.1016\/S1470-2045(20)30456-3"},{"issue":"10","key":"1694_CR47","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(20)30454-X.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1694_CR48","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","volume":"35","author":"CC Parker","year":"2024","unstructured":"Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol. 2024;35(7):656\u201366. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.010.","journal-title":"Ann Oncol"},{"issue":"10260","key":"1694_CR49","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396(10260):1422\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(20)31952-8.","journal-title":"Lancet"},{"issue":"12","key":"1694_CR50","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magn\u00e9 N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30486-3.","journal-title":"Lancet Oncol"},{"issue":"10442","key":"1694_CR51","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","volume":"403","author":"CC Parker","year":"2024","unstructured":"Parker CC, Kynaston H, Cook AD, et al. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet. 2024;403(10442):2416\u201325. https:\/\/doi.org\/10.1016\/S0140-6736(24)00549-X.","journal-title":"Lancet"},{"key":"1694_CR52","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1200\/JCO.2023.41.6_suppl.303","volume":"41","author":"PL Nguyen","year":"2023","unstructured":"Nguyen PL, et al. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate\/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). JCO. 2023;41:303\u2013303. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.303.","journal-title":"JCO"},{"issue":"1","key":"1694_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022;208(1):19\u201325. https:\/\/doi.org\/10.1097\/JU.0000000000002758.","journal-title":"J Urol"},{"issue":"3","key":"1694_CR54","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1464-410X.2010.09565.x","volume":"107","author":"SA Siddiqui","year":"2011","unstructured":"Siddiqui SA, Boorjian SA, Blute ML, et al. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int. 2011;107(3):383\u20138. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09565.x.","journal-title":"BJU Int"},{"key":"1694_CR55","doi-asserted-by":"publisher","unstructured":"Hussain M, Tangen CM, Thompson IM Jr, et al. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 [published correction appears in J Clin Oncol. 2018 Jul 10;36(20):2131. https:\/\/doi.org\/10.1200\/JCO.2018.00.0332.].\u00a0J Clin Oncol. 2018;36(15):1498\u20131504. https:\/\/doi.org\/10.1200\/JCO.2017.76.4126","DOI":"10.1200\/JCO.2018.00.0332"},{"key":"1694_CR56","doi-asserted-by":"publisher","unstructured":"Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy [published correction appears in J Clin Oncol. 2007 Sep 10;25(26):4153].\u00a0J Clin Oncol. 2007;25(15):2035\u20132041. https:\/\/doi.org\/10.1200\/JCO.2006.08.9607","DOI":"10.1200\/JCO.2006.08.9607"},{"issue":"5","key":"1694_CR57","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.eururo.2019.12.020","volume":"77","author":"DW Lin","year":"2020","unstructured":"Lin DW, Shih MC, Aronson W, et al. Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study. Eur Urol. 2020;77(5):563\u201372. https:\/\/doi.org\/10.1016\/j.eururo.2019.12.020.","journal-title":"Eur Urol"},{"issue":"4","key":"1694_CR58","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/JU.0000000000003891","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA\/ASTRO\/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024;211(4):518\u201325. https:\/\/doi.org\/10.1097\/JU.0000000000003891.","journal-title":"J Urol"},{"key":"1694_CR59","unstructured":"NRG Oncology. Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03371719"},{"issue":"10","key":"1694_CR60","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1200\/JCO.23.01157","volume":"42","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal R, Heller G, Hillman DW, et al. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024;42(10):1114\u201323. https:\/\/doi.org\/10.1200\/JCO.23.01157.","journal-title":"J Clin Oncol"},{"key":"1694_CR61","unstructured":"NRG Oncology. Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer. Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04134260"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01694-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01694-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01694-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:04:04Z","timestamp":1757552644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01694-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":61,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1694"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01694-y","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"26 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. McKay reports consultant for Ambrx, Arcus, AstraZeneca, Aveo, Bayer, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera, Caris, Daiichi Sankyo, Dendreon, Exelixis, Johnson & Johnson, Lilly, Merck, Neomorph, Nimbus, Novartis, Pfizer, Precede, Sanofi, SeaGen, Sorrento Therapeutics, Sumitomo Pharma (formerly Myovant), Telix.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}